EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team

Nanae Tsuruoka iD, Hironobu Takedomi, Yasuhisa Sakata, Shin Fujioka, Ryosuke Sakemi, Shinya Ashizuka, Nobuaki Nishimata, Kazumi Inaba, Shuji Kanmura, Tetsu Kinjo, Yoki Furuta, Shinichiro Yoshioka und 4 weitere

Journal of Gastroenterology · 2026-07 · 61 (7) · 953-961

DOI: 10.1007/s00535-026-02383-8 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, online erschienen am 10.03.2026. Verfasst von Nanae Tsuruoka und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1, Nabeshima, Saga, 849-8501, Japan. tsuruok…. Hauptthemen laut MEDLINE: Latent Tuberculosis, Immunosuppressive Agents, Inflammatory Bowel Diseases. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Screening and preventive treatment are recommended for latent tuberculosis infection (LTBI) before immunosuppressive therapy in patients with inflammatory bowel disease (IBD). However, the prevalence of LTBI and active tuberculosis, combined with their influence on selection of immunosuppressive therapy, remains uncertain. This retrospective multicenter study aimed to determine the prevalence of LTBI and to evaluate therapeutic management in Japanese patients with IBD according to tuberculosis infection status. METHODS: The clinical profiles and therapeutic management of patients with IBD who were screened for LTBI at any of 10 Japanese institutions between July 2010 and June 2020 were identified by review of the electronic medical records. LTBI was defined as positive when an interferon-gamma release assay or tuberculin test was positive with a normal chest radiograph. RESULTS: A total of 4257 patients with IBD (Crohn's disease, n = 1646; ulcerative colitis, n = 2611) were included. Sixty-nine patients (1.62%) tested positive for LTBI. Ustekinumab and vedolizumab were used significantly more often in the LTBI group than in the non-LTBI group. Fifty-seven patients (82.6%) in the LTBI group received preventive treatment, while 12 (17.4%) were followed without treatment; only ustekinumab and vedolizumab were selected as advanced therapies. During follow-up, two patients developed active tuberculosis after preventive therapy while receiving immunosuppressive agents. CONCLUSIONS: The prevalence of LTBI among Japanese patients with IBD was 1.62%. Both LTBI status and use of preventive treatment may influence selection of advanced therapies for IBD. Although rare, active tuberculosis can occur despite preventive treatment, highlighting the need for appropriate monitoring strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Latent TuberculosisImmunosuppressive AgentsInflammatory Bowel DiseasesHumansRetrospective StudiesJapanFemaleMalePrevalenceMiddle AgedAdultInterferon-gamma Release TestsTuberculin TestAgedYoung Adult

Stichwörter der Autor:innen

Immunosuppressive therapyInflammatory bowel diseaseLatent tuberculosis infection

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1, Nabeshima, Saga, 849-8501, Japan. tsuruoka@cc.saga-u.ac.jp.
  • Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1, Nabeshima, Saga, 849-8501, Japan.
  • Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Gastroenterology, Tobata Kyoritsu Hospital, Kitakyushu, Japan.
  • Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
  • Department of Internal Medicine, Junaikai Medical Corporation Sameshima Hospital, Kagoshima, Japan.

ORCID-Profile: Nanae Tsuruoka

Zitieren

APA

Tsuruoka, N., Takedomi, H., Sakata, Y., Fujioka, S., Sakemi, R., Ashizuka, S., Nishimata, N., Inaba, K., Kanmura, S., Kinjo, T., Furuta, Y., Yoshioka, S., Yamamoto, S., Takamori, A., Hirai, F., & Esaki, M. (2026). Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team. Journal of Gastroenterology, 61(7), 953-961. https://doi.org/10.1007/s00535-026-02383-8

Vancouver

Tsuruoka N, Takedomi H, Sakata Y, Fujioka S, Sakemi R, Ashizuka S, et al. Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team. Journal of Gastroenterology. 2026;61(7):953-961. doi:10.1007/s00535-026-02383-8

BibTeX
@article{Tsuruoka2026,
  author = {Tsuruoka, Nanae and Takedomi, Hironobu and Sakata, Yasuhisa and Fujioka, Shin and Sakemi, Ryosuke and Ashizuka, Shinya and Nishimata, Nobuaki and Inaba, Kazumi and Kanmura, Shuji and Kinjo, Tetsu and Furuta, Yoki and Yoshioka, Shinichiro and Yamamoto, Shojiro and Takamori, Ayako and Hirai, Fumihito and Esaki, Motohiro},
  title = {Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team},
  journal = {Journal of Gastroenterology},
  year = {2026},
  volume = {61},
  number = {7},
  pages = {953--961},
  doi = {10.1007/s00535-026-02383-8}
}
Kostenlos starten →